Skip to main content
. 2022 Aug 10;187(6):866–877. doi: 10.1111/bjd.21743

Figure 1.

Figure 1

CONSORT diagram: study patient disposition during the induction and maintenance periods. D/C, discontinued; ITT, intention to treat; Miri, mirikizumab; Q4W, every 4 weeks; Q8W, every 8 weeks. aIncludes eight patients who met the relapse criteria at week 52 and then completed the maintenance period without retreatment. bThe eight patients who met the relapse criteria at week 52 and then completed the maintenance period without retreatment are not included here.